Biosimilar Podium Promotion: FDA Emphasizes Advantages Of Abbreviated Pathway
Biosimilar products are not intended to be stand-alone development programs, agency stresses, noting that early analytical data can allow for more targeted clinical trials later.
You may also be interested in...
FDA wants panels to look more closely at analytics in lesson learned from Zarxio meeting.
Extrapolation, uncertainty could prove important when the Oncologic Drugs Advisory Committee considers Sandoz’s filgrastim biosimilar on Jan. 7.
January meeting date suggests FDA’s review of Sandoz’s abridged filgrastim application is on track, but Oncologic Drugs Advisory Committee could be challenged by differences between biosimilar and conventional BLA development.